FDA Clearance Tracker · P930036-S021
Atellica IM Alpha Fetoprotein (AFP)
Last checked: Nov 20, 2026Latest source record: Feb 8, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Feb 8, 2024
Approved
Time to decision
178 days
Received Aug 14, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P930036-S021
- Device name
- Atellica IM Alpha Fetoprotein (AFP)
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Applicant location
- East Walpole, MA
- Received
- Aug 14, 2023
- Decided
- Feb 8, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P930036
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
migration of the ADVIA Centaur AFP assay to the Atellica CI Analyzer
Source documents
Other decisions for Siemens Healthcare Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.